204 related articles for article (PubMed ID: 25744342)
21. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
22. Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.
Cardinale D; Biasillo G; Cipolla CM
Curr Cardiol Rep; 2016 Jun; 18(6):51. PubMed ID: 27108361
[TBL] [Abstract][Full Text] [Related]
23. The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients.
Pitekova B; Ravi S; Shah SV; Mladosievicova B; Heitner S; Ferencik M
Curr Cardiol Rep; 2016 Sep; 18(9):87. PubMed ID: 27443383
[TBL] [Abstract][Full Text] [Related]
24. Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments.
Ahmed SH; Moussa Sherif DE; Fouad Y; Kelany M; Abdel-Rahman O
Expert Opin Drug Saf; 2016 Jul; 15(7):911-23. PubMed ID: 27007468
[TBL] [Abstract][Full Text] [Related]
25. Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial.
Brain EG; Mertens C; Girre V; Rousseau F; Blot E; Abadie S; Uwer L; Bourbouloux E; Van Praagh-Doreau I; Mourey L; Kirscher S; Laguerre B; Fourme E; Luneau S; Genève J; Debled M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):160-70. PubMed ID: 21035352
[TBL] [Abstract][Full Text] [Related]
26. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot).
Maggioni AP; Dahlström U; Filippatos G; Chioncel O; Crespo Leiro M; Drozdz J; Fruhwald F; Gullestad L; Logeart D; Fabbri G; Urso R; Metra M; Parissis J; Persson H; Ponikowski P; Rauchhaus M; Voors AA; Nielsen OW; Zannad F; Tavazzi L;
Eur J Heart Fail; 2013 Jul; 15(7):808-17. PubMed ID: 23537547
[TBL] [Abstract][Full Text] [Related]
27. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
[TBL] [Abstract][Full Text] [Related]
28. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
Zamorano JL; Lancellotti P; Rodriguez Muñoz D; Aboyans V; Asteggiano R; Galderisi M; Habib G; Lenihan DJ; Lip GYH; Lyon AR; Lopez Fernandez T; Mohty D; Piepoli MF; Tamargo J; Torbicki A; Suter TM;
Eur Heart J; 2016 Sep; 37(36):2768-2801. PubMed ID: 27567406
[No Abstract] [Full Text] [Related]
29. Cardiotoxic heart failure in breast cancer survivors: a concept analysis.
Harrison JM; Pressler SJ; Friese CR
J Adv Nurs; 2016 Jul; 72(7):1518-28. PubMed ID: 27126746
[TBL] [Abstract][Full Text] [Related]
30. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues.
Marwick TH
Can J Cardiol; 2016 Jul; 32(7):842-6. PubMed ID: 27343742
[TBL] [Abstract][Full Text] [Related]
31. Cardioncology: state of the heart.
Todaro MC; Oreto L; Qamar R; Paterick TE; Carerj S; Khandheria BK
Int J Cardiol; 2013 Sep; 168(2):680-7. PubMed ID: 23639459
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
Eschenhagen T; Force T; Ewer MS; de Keulenaer GW; Suter TM; Anker SD; Avkiran M; de Azambuja E; Balligand JL; Brutsaert DL; Condorelli G; Hansen A; Heymans S; Hill JA; Hirsch E; Hilfiker-Kleiner D; Janssens S; de Jong S; Neubauer G; Pieske B; Ponikowski P; Pirmohamed M; Rauchhaus M; Sawyer D; Sugden PH; Wojta J; Zannad F; Shah AM
Eur J Heart Fail; 2011 Jan; 13(1):1-10. PubMed ID: 21169385
[TBL] [Abstract][Full Text] [Related]
33. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
35. Long term side effects of adjuvant chemotherapy in patients with early breast cancer.
Tao JJ; Visvanathan K; Wolff AC
Breast; 2015 Nov; 24 Suppl 2(0 2):S149-53. PubMed ID: 26299406
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects.
Reichman BS; Green KB
J Natl Cancer Inst Monogr; 1994; (16):125-9. PubMed ID: 7999454
[TBL] [Abstract][Full Text] [Related]
37. Cardiotoxicity of systemic agents used in breast cancer.
Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
39. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
Zamorano JL; Lancellotti P; Rodriguez Muñoz D; Aboyans V; Asteggiano R; Galderisi M; Habib G; Lenihan DJ; Lip GY; Lyon AR; Lopez Fernandez T; Mohty D; Piepoli MF; Tamargo J; Torbicki A; Suter TM; Zamorano JL; Aboyans V; Achenbach S; Agewall S; Badimon L; Barón-Esquivias G; Baumgartner H; Bax JJ; Bueno H; Carerj S; Dean V; Erol Ç; Fitzsimons D; Gaemperli O; Kirchhof P; Kolh P; Lancellotti P; Lip GY; Nihoyannopoulos P; Piepoli MF; Ponikowski P; Roffi M; Torbicki A; Vaz Carneiro A; Windecker S; ; ;
Eur J Heart Fail; 2017 Jan; 19(1):9-42. PubMed ID: 27565769
[No Abstract] [Full Text] [Related]
40. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts.
van de Poll-Franse LV; Horevoorts N; van Eenbergen M; Denollet J; Roukema JA; Aaronson NK; Vingerhoets A; Coebergh JW; de Vries J; Essink-Bot ML; Mols F;
Eur J Cancer; 2011 Sep; 47(14):2188-94. PubMed ID: 21621408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
